In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Mirna Therapeutics Inc. (NASDAQ:MIRN) reported that Opaleye Management has picked up 9 of common stock as of 2017-06-29.
The acquisition brings the aggregate amount owned by Opaleye Management to a total of 9 representing a 11% stake in the company.
For those not familiar with the company, Mirna Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of micro ribonucleic acid (RNA)-based oncology therapeutics. The Company is developing mimics of naturally occurring microRNAs that are designed to restore the tumor suppressor activity and aid appropriate anti-tumor immune response. This approach is known as microRNA replacement therapy. Its lead product candidate, MRX34, a mimic of naturally occurring microRNA-34 (miR-34) encapsulated in a liposomal nanoparticle formulation, has demonstrated clinical proof of concept as a single agent in its ongoing Phase I clinical trial. The Company’s RNA molecules function as natural microRNAs when they enter human cells. These RNA molecules, which it calls microRNA mimics, may be used to replace those tumor suppressor microRNAs that are lost, or under expressed, in cancer cells. Its other preclinical product candidates include miR-215, miR-101, miR-16 and let-7.
A glance at Mirna Therapeutics Inc. (NASDAQ:MIRN) key stats reveals a current market capitalization of $35.25 Million based on $20.86 Million shares outstanding and a price at last close of $1.69 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2015-10-06, Pfizer picked up 714,285 at a purchase price of $7.00. This brings their total holding to 2,253,509 as of the date of the filing.
On the sell side, the most recent transaction saw Irvin unload 280 shares at a sale price of $1.43. This brings their total holding to 7,625.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an Mirna Therapeutics Inc. (NASDAQ:MIRN) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.